Single Cell Analysis Systems for Therapeutic Discovery Name

Single Cell Analysis Systems for Therapeutic Discovery Name, Date and Conference/Client Title 3 rd February 2016.

COMPANY INTRODUCTION Ø Sphere Fluidics (SF) is an established Life Sciences Tools spin-out from the University of Cambridge focussing on Single Cell Analysis. Ø Originally commercialised Research Instruments and Consumables (c. 40 products) and R&D Collaborations to generate rapid income and learn the market. Ø Strategy has evolved to now developing Industrial Systems that enable rapid ultra-high-throughput discovery of therapeutics from single cells (e. g. Cyto-Mine®). Ø IP Protection: 54 patents and 2 Trademarks created £ 12 M of grants and funding. with over Ø Raised £ 4 M in funding to date, income-generating and now raising ~£ 6 M (£ 4. 6 M already committed; Pre-money of £ 10 M).

Core Technology: Encapsulation and Assay of Single Cells in Picodroplets Name, Date and Conference/Client Title

PICODROPLETS – MINIATURE “TEST TUBES” FOR SINGLE CELLS Novel microfluidics can produce, manipulate, analyse, sort, fuse, split, retrieve and dispense millions of picodroplets per biochip per day. Picodroplets are small volume (pl-nl) aqueous droplets in oil made at rates of > 100, 000 per min. They enable testing of trapped, secreted molecules (e. g. antibodies). Cells Picodroplets are stabilised using novel biocompatible surfactants and are useful for many weeks. A microfluidic biochip (a few cms in size) Oil Picodroplets containing single cells Oil Stored picodroplets

EXAMPLE PICODROPLET OPERATIONS Cell encapsulation Picodroplet splitting Sorting Spacing Cell growth (e. g. T-cells) Fusion Cell division occurs within 48 hours

SF TECHNOLOGY: FEATURES AND BENEFITS Ø High-throughput: can perform millions of single cell tests per biochip and isolate rare variants from a vast population. Ø Miniaturised: can save up to £ 0. 5 M per R&D program (e. g. GSK). Ø Enabling: Screen entire libraries significantly improving rates of finding unique variants or high expressors. Ø Picodroplet fusion: enables inline co-incubation and novel functional assays – impossible to do by conventional techniques. Ø Picodroplet splitting: facilitates mass spectrometry and other analyses allowing retrieval of “hit” replicates - gives > 20 -fold faster analysis.

Target markets Name, Date and Conference/Client Title

PRIORITISED MARKETS (ADDRESSABLE) - A £BILLION 1) Biopharmaceutical Discovery & Development (£ 214 MM growing at 10% p. a. ). 2) Synthetic Biology - Bioprocessing (£ 135 MM growing at 42% p. a. ). 3) Stem Cell Engineering, Isolation and Analysis (£ 580 MM growing at 14% p. a. ). 4) Single Cell Disease Research (Infectious Diseases: £ 60 MM growing at 6% p. a. ). 5) Single Cell Diagnostics and Prognostics - Cancer Market (Total): £ 20 billion growing at 15% p. a.

Cyto-Mine®: Next Generation Platform for Biopharmaceutical Discovery and Development Name, Date and Conference/Client Title

CYTO-MINE® (THE INDUSTRIAL SYSTEM) OVERVIEW The Single Cell Analysis & Monoclonality Assurance System: Ø Single cell analysis, cloning and isolation techniques are critical for biopharmaceutical discovery and development. Ø Conventional techniques offer partial solutions performing some of the following: high-throughput screening, protein secretion assays, rapid cell sorting, single cell dispensing to microplates and monoclonality verification. Ø Cyto-Mine® will be the world’s first integrated device specifically designed to automatically perform all of these functions in a single system.

COMPETITIVE ADVANTAGE OF CYTO-MINE®

PROJECTED SALES: CYTO-MINE® PRIMARY MARKET Cyto-Mine®: An integrated, high-throughput single cell analysis platform using optical detection. Primary Market: Biopharmaceuticals Addressable User Base: 480 international Biopharma firms, CROs and Core Labs Addressable Market: £ 214 MM.

PROJECTED SALES: CYTO-MINE® IN ALL 5 MARKETS

Financial Projections Name, Date and Conference/Client Title

FINANCIAL PROJECTIONS 44 Cyto-Mine® Units Sold: 0 3 15 27 Other Instruments Sold: 0 4 0 0 41 15 23

USE OF FUNDS Ø Raising circa. £ 6 M of investment (Pre-money: £ 10 M; £ 4. 6 M already committed), ~£ 1. 4 M investment opportunity to: Ø Commercialise the world‘s first integrated, single cell analysis system (Cyto-Mine®) in Biopharmaceutical Discovery and Devt. Ø Position Cyto-Mine® technology into other new markets. Ø Progress development and sales of the ESI-Mine™ system. Ø Enable expansion of facility, the commercial and technical teams. Ø Exit is by Trade Sale within the next 3 - 4 years to a global, Life Sciences company for £ 100 M - £ 200 M. Ø Full business plan and due diligence materials available.

THANK YOU Ø Investor Meetings: Ongoing. Ø Key Contact: Dr. Frank F. Craig CEO, Sphere Fluidics Ltd Tel: +44 7805 659566 / +44 1223 804201 E-mail: Frank. Craig@spherefluidics. com